Barrons.com11d agoneutral
Gilead Posts a Loss on Acquisitions but Revenue Tells a Bigger StoryGilead Sciences posts higher revenue as its market-leading HIV drug portfolio continues to drive growth.
Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
39last 24h
1802last 7d
299● bullish (7d)
170● bearish (7d)
205publishers
MarketBeat23d agoneutral
Organon & Co. Shareholders Clear Sun Pharma Merger DealShareholders of Organon & Co. (NYSE:OGN) approved the company’s proposed merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a virtual special meeting held Wednesday, according to preliminary voting results announced during the meeting. The special meeting was convened solely to cons
Barrons.com59d agoneutral
How America Got to SpaceX: The Long Trail of Big IPOs That Began in 1783SpaceX’s $75 billion initial public offering shattered market records, turned founder Elon Musk into the world’s first trillionaire, and opened fresh debates over corporate valuations and governance. It’s not the first time an IPO has shaken things up. IPOs have been reshaping markets since the Bank of North America’s 1783 debut got it all started for the young republic.
Investor's Business Daily75d agoneutral
Stock Market Today: Dow Rises Amid Continued U.S.-Iran Deal Hopes; Nvidia Rallies On New Chip (Live Coverage)Stock Market Today: The Dow Jones index rose Monday amid ongoing hopes for a U.S.-Iran deal. Nvidia stock jumped on a new chip.